Germline biomarkers predict toxicity to anti-PD1/PDL1 checkpoint therapy.
Joanne B WeidhaasNicholas MarcoAaron W SchefflerAnusha KalbasiKirk WileniusEmily RietdorfJaya GillMara HeiligCaroline DeslerRobert K ChinTania KaprealianSusan McCloskeyAnn RaldowNaga P RajaSantosh KesariJose CarrilloAlexandra DrakakiMark ScholzDonatello TelescaPublished in: Journal for immunotherapy of cancer (2022)
A germline microRNA-based biomarker signature predicts grade 2 and higher irAEs to anti-PD1/PDL1 therapy, regardless of tumor type, in a pan-cancer manner. These findings represent an important step toward personalizing checkpoint therapy, the use of which is growing rapidly.